Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Pharmaceuticals (Basel) ; 17(2)2024 Jan 28.
Article in English | MEDLINE | ID: mdl-38399382

ABSTRACT

Dopamine and serotonin receptors and transporters play an essential role in the pathophysiology of schizophrenia; changes in their expression have been reported in neurons and leukocytes. Each antipsychotic induces a unique pattern in leukocyte function and phenotype. However, the use of polytherapy to treat schizophrenia makes it challenging to determine the specific effects of risperidone on peripheral blood mononuclear cells (PBMCs). The aim of this study was to evaluate the changes in the expression of D3, D5, DAT, 5-HT2A, and SERT in PBMCs from healthy volunteers (HV), drug-naive patients with schizophrenia (PWS), drug-free PWS, and PWS treated with risperidone for up to 40 weeks using quantitative PCR. Our study revealed elevated mRNA levels of D3, DAT, 5-HT2A, and SERT in unmedicated PWS. Treatment with risperidone led to a reduction only in the expression of 5-HT2A and SERT. Furthermore, we observed a moderate correlation between 5-HT2A expression and the positive and negative syndrome scale (PANSS), as well as SERT expression and PANSS scale. We also found a moderate correlation between 5-HT2A and SERT expression and the positive subscale. The duration of risperidone consumption had a significant negative correlation with the expression of 5-HT2A and SERT. Our study introduces the measurement of 5-HT2A and SERT expression in PBMCs as a useful parameter for assessing the response to risperidone in PWS.

2.
Actas Esp Psiquiatr ; 51(4): 176-183, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37817737

ABSTRACT

Impairment in attention, memory, processing speed and executive functions have been described in patients with schizophrenia. Such impairments can be observed in early stages of the disease and in chronic patients; discrepancy in findings regarding the cognitive deficits at different stages of the illness keeps the debate about schizophrenia as a neurodegenerative condition which courses with continuous deterioration, or if deficits remain stable, as the neurodevelopmental hypothesis suggests.


Subject(s)
Cognition Disorders , Cognitive Dysfunction , Schizophrenia , Humans , Schizophrenia/complications , Neuropsychological Tests , Cognitive Dysfunction/etiology , Cognition Disorders/complications , Cognition Disorders/psychology , Executive Function
3.
Actas esp. psiquiatr ; 51(4): 176-183, Julio - Agosto 2023. tab
Article in Spanish | IBECS | ID: ibc-226455

ABSTRACT

Se ha descrito la presencia de déficits cognitivos en pacientes con esquizofrenia, dichas alteraciones pueden observarse en fases tempranas y crónicas de la enfermedad.Sin embargo, los hallazgos respecto a los déficits en estas fases aún mantienen el debate sobre si la esquizofrenia es una condición neurodegenerativa que cursa con un deterioro continuo o si los déficits permanecen estables, como sugiere la hipótesis del neurodesarrollo. En el presente estudio se compara el rendimiento cognitivo de pacientes con esquizofrenia de inicio reciente (RO) y pacientes crónicos (CH) con la finalidad de contrastar la hipótesis del neurodesarrollo con la perspectiva neurodegenerativa. Método. Se incluyeron 20 participantes de RO (< 5 años desde el primer episodio psicótico) y 30 pacientes de CH (>5 años desde el primer episodio psicótico). Para la evaluación cognitiva se utilizó la Batería Cognitiva Consensuada MATRICS (MCCB), la Prueba Torre de Londres, la Prueba de Clasificación de Tarjetas de Wisconsin y la Prueba de Stroop. Se utilizó ANCOVA para las comparaciones de grupos. Resultados. No hubo diferencias entre los grupos en la mayoría de las pruebas cognitivas. Se observó una diferencia significativa en la prueba de span espacial del MCCB. Conclusiones. Los déficits cognitivos permanecen estables a lo largo del tiempo; nuestros hallazgos son consistentes con la hipótesis del neurodesarrollo de la esquizofreniamás que con el enfoque neurodegenerativo. (AU)


Impairment in attention, memory, processing speed and executive functions have been described in patients with schizophrenia. Such impairments can be observed in early stages of the disease and in chronic patients; discrepancy in findings regarding the cognitive deficits at different stages of the illness keeps the debate about schizophrenia as a neurodegenerative condition which courses with continuous deterioration, or if deficits remain stable, as the neurodevelopmental hypothesis suggests. The aim of the present study was to compare the cognitive performance of recent-onset (RO) and chronic (CH) schizophrenia patients to contrast the neurodevelopmental hypothesis against the neurodegenerative approach. Methods. Twenty RO participants (< 5 years from first psychotic episode) and 30 CH patients (> 5 years from first psychotic episode) were included in the sample. The MATRICS Consensus Cognitive Battery (MCCB), Tower of London test (ToL), Wisconsin Card Sorting Test (WCST) and Stroop Test were used for cognitive evaluation. ANCOVA analysis was performed for group comparisons. Results. No differences between RO and CH patients were identified on most cognitive tests. However, a significant difference was observed in the visual spatial span test from MCCB. Conclusions. We conclude that cognitive deficits remain stable over the course of the disease. Our findings are consistent with the neurodevelopmental hypothesis of schizophrenia rather than the neurodegenerative approach. (AU)


Subject(s)
Humans , Schizophrenia/therapy , Chronic Disease , Neurodevelopmental Disorders/therapy
4.
Heliyon ; 8(7): e09899, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35874061

ABSTRACT

To evaluate the putative detrimental effect of Major Depressive Disorder (MDD) on the cognitive impairment associated with Alcohol Dependence (AD), we contrasted the neuropsychological profile and behavioral responses of AD subjects, MDD individuals, and in those with a co-occurring AD-MDD diagnosis (DD). Patients and healthy subjects completed a comprehensive neuropsychological battery and were recorded for P200, P300, and N450 event-related potentials during memory and Stroop tasks. AD subjects exhibited a generalized detrimental neuropsychological performance; in contrast, in MDD individuals, impairment was limited to discrete domains. Notably, the deficits were distinctive in DD cases. A P200 increased amplitude in MDD, a decrease in P300 amplitude in AD, and increased latency of P300 in DD patients were the overt electrophysiological abnormalities identified. Dual patients also exhibited a distinct pattern of behavioral responses, particularly apparent during high-demand cognitive tasks. Specific ERP adjustments were associated with the short-term fluoxetine treatment in DD and MDD subjects; the SSRI also improved altered baseline performance in learning and cognitive flexibility in DD subjects. In conclusion, the neuropsychological and behavioral alterations detected in the co-occurrence of AD-MDD did not seem to be merely the sum of the negative contributions of the independent disorders.

5.
Neurocase ; 27(5): 385-390, 2021 10.
Article in English | MEDLINE | ID: mdl-34565291

ABSTRACT

This case study describes the coexistence of Capgras and Fregoli-type delusions in a 51-year-old woman. The patient reported that her children were kidnapped and replaced with doubles. She claims that several customers at her shop are her real children. Neuropsychological assessment revealed severe defects in social cognition and an increased number of perseveration responses in the self-directed signaling task. We propose that the latter finding is a measure of the familiarity phenomenon and may be associated with hypofunction in the left retrosplenial region. SPECT-CT confirmed a pattern of hypoperfusion in the retrosplenial, posterior cingulate, and prefrontal cortex.


Subject(s)
Capgras Syndrome , Child , Delusions/etiology , Female , Humans , Middle Aged , Neuropsychological Tests , Recognition, Psychology
6.
Neuropsychobiology ; 80(1): 45-51, 2021.
Article in English | MEDLINE | ID: mdl-32516783

ABSTRACT

INTRODUCTION: Schizoaffective disorder (SA) is classified into bipolar (bSA) and depressive (dSA) subtypes. Although clinical differences between both have been reported, there is no clear information regarding their specific cognitive profile. OBJECTIVE: To compare neurocognition between SA subtypes and schizophrenia (SC). METHODS: A total of 61 patients were assessed and divided into 3 groups: 35 SC, 16 bSA, and 10 dSA. All participants signed an informed consent letter. The MATRICS Consensus Cognitive Battery, Central and South American version was used to assess neurocognition. The study was performed at the Instituto Nacional de Psiquiatría "Ramón de la Fuente". Participants were identified by specialized psychiatrists. Trained neuropsychologists carried out the clinical and cognitive assessment, which lasted 2 h approximately. RESULTS: The cognitive assessment showed a significant difference in Trail Making Test part A subtest (F[2,58] = 4.043; p = 0.023]. Post hoc analyses indicated that dSA obtained a significantly higher score than SC (MD = -11.523; p = 0.018). The f test showed a large effect size (f = 0.401). No statistical differences were observed regarding other cognitive variables. CONCLUSIONS: The cognitive profile of SA subtypes and SC is similar since no differences were found in most subtests. However, dSA may be less impaired than SC in measures of processing speed. Further research with larger samples must be conducted.


Subject(s)
Affective Disorders, Psychotic/physiopathology , Bipolar Disorder/physiopathology , Cognitive Dysfunction/physiopathology , Depressive Disorder/physiopathology , Psychotic Disorders/physiopathology , Schizophrenia/physiopathology , Adult , Affective Disorders, Psychotic/complications , Bipolar Disorder/complications , Cognitive Dysfunction/etiology , Depressive Disorder/complications , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Psychotic Disorders/complications , Schizophrenia/complications
7.
Salud ment ; 43(1): 21-25, Jan.-Feb. 2020. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1115925

ABSTRACT

Abstract Introduction Several studies have explored the relationship between serum prolactin levels, symptomatology, and cognitive dysfunction in individuals at high risk for psychosis and patients with a first psychotic episode. However, the relationship between such variables is poorly understood in the case of chronic patients. Objective To assess the relationship between prolactin levels, neuropsychological impairment, and symptom severity in patients with chronic schizophrenia. Method A total of 31 patients with diagnosis of schizophrenia were evaluated between May and December 2018. The age range was 18 to 60 years, with patients receiving antipsychotic treatment during a month at least. Data was obtained from clinical records, interviews, clinimetry, and with the application of the PANSS and the MCCB battery. For the prolactin measurement, the analysis was performed on a sample of 500 microliters of serum, with a chemiluminescence technique. Results The sample was comprised mostly by men (77.4%), with a mean age of 37.65 years, 13.29 years of formal education, and disease duration of 11.58 years. No correlations were observed between prolactin levels and PANSS components and subscales. Only in male patients is there a negative correlation was found between prolactin levels with the overall combined score of the MCCB battery and cognitive domains of reasoning and verbal learning. Discussion and conclusions Men diagnosed with schizophrenia may be particularly vulnerable to the negative effects of hyperprolactinemia on cognition. These preliminary data have clinical implications for close monitoring of prolactin and cognitive decline in males with schizophrenia. Theoretically, these data are suggestive of a protective effect of hormones in women with this condition.


Resumen Introducción Diversos estudios han explorado la relación entre los niveles de prolactina sérica, la sintomatología y la disfunción cognitiva en individuos con alto riesgo de psicosis y pacientes con un primer episodio psicótico. Sin embargo, la relación entre tales variables es poco comprendida en el caso de los pacientes crónicos con esquizofrenia. Objetivo Evaluar la relación entre los niveles de prolactina, el deterioro neuropsicológico y la severidad de los síntomas en pacientes crónicos. Método Se evaluó un total de 31 pacientes. El rango de edad fue de 18 a 60 años, quienes recibieron tratamiento antipsicótico durante un mes como mínimo. Los datos se obtuvieron de entrevistas y de la aplicación de la PANSS y la MCCB. La medición de la prolactina se realizó con una muestra de 500 microlitros de suero, con una técnica de quimioluminiscencia. Resultados La muestra estuvo compuesta en su mayoría por hombres (77.4%), con una edad media de 37.65 años, 13.29 años de escolaridad y una duración de la enfermedad de 11.58 años. No se observaron correlaciones entre los niveles de prolactina y los componentes y subescalas del PANSS. Sólo en los pacientes varones se da una correlación negativa entre los niveles de prolactina con la puntuación global combinada de la batería de MCCB y los dominios cognitivos de razonamiento y aprendizaje verbal. Discusión y conclusiones Los hombres diagnosticados con esquizofrenia pueden ser particularmente vulnerables a los efectos negativos de la hiperprolactinemia sobre la cognición. Teóricamente, estos datos sugieren un efecto protector de las hormonas en las mujeres con esta enfermedad.

8.
Psychiatr Danub ; 31(3): 355-357, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31596829

ABSTRACT

We aimed to compare processing speed (PS) and its subcomponents in schizophrenia (SC) and schizoaffective disorder (SA). Thirty-five patients were divided into two groups (SC=18; SA=17). PS tasks from the MATRICS Consensus Cognitive Battery Central/South America version were used. Additional PS subcomponents were analyzed (i.e., behavioral execution, response processing, and accuracy). SA obtained significant higher scores than SC in response processing, verbal fluency and the PS general domain. Our results indicate that PS is a potential cognitive marker to differentiate between SC and SA. Further research with larger samples must be conducted.


Subject(s)
Cognition Disorders/physiopathology , Cognition Disorders/psychology , Psychotic Disorders/physiopathology , Psychotic Disorders/psychology , Schizophrenia/physiopathology , Schizophrenic Psychology , Cognition Disorders/complications , Humans , Neuropsychological Tests , Pilot Projects , Psychotic Disorders/complications , Schizophrenia/complications
9.
Arch Clin Neuropsychol ; 32(3): 369-374, 2017 May 01.
Article in English | MEDLINE | ID: mdl-28431032

ABSTRACT

OBJECTIVE: To provide a brief presentation of preliminary data on rehabilitation services provided by clinical neuropsychologists within the United States. METHOD: This survey utilized data extracted from a larger international research study conducted in 39 countries including N = 173 professionals who reported to engage in neuropsychological rehabilitative services within the past year (63.6% female, 44.36 ± 11.83 years of age) took part in the study. RESULTS: Neuropsychologists providing rehabilitation services in the United States in the past year were more likely to provide individual versus group therapy, likely to employ technology (e.g., personal computers, mobile phones/smartphones) as part of treatment services, see a range of diagnostic groups most prominently traumatic brain injury and stroke/vascular conditions, and work to address a range of both cognitive (e.g., memory, attention/concentration, and executive functioning) and psychological (e.g., emotional/behavioral adjustment and well-being, awareness of disability/disease) issues. CONCLUSIONS: Prior published surveys suggest that clinical neuropsychologists have a growing involvement in rehabilitation services within the United States but with little clarity as to the actual characteristics of actual professional activities and practices. The present study aimed to provide such information and hopefully will be helpful in promoting additional systematic studies in this area.


Subject(s)
Brain Injuries, Traumatic/complications , Cognitive Dysfunction/therapy , Cognitive Remediation/statistics & numerical data , Neurological Rehabilitation/statistics & numerical data , Neuropsychology/statistics & numerical data , Psychotherapy/statistics & numerical data , Stroke/complications , Cognitive Dysfunction/etiology , Humans , United States
10.
Psiquiatr. biol. (Internet) ; 22(3): 71-76, sept.-dic. 2015. tab
Article in Spanish | IBECS | ID: ibc-146790

ABSTRACT

La comorbilidad entre el trastorno depresivo mayor (TDM) y dependencia de alcohol (DA) se conoce como diagnóstico dual (DD). Se ha sugerido que los pacientes con esta comorbilidad presentan síntomas anímicos y neurovegetativos de mayor gravedad en comparación con los pacientes de diagnóstico único. Sin embargo, el efecto aditivo de los déficits cognitivos en esta población ha sido escasamente explorado. El objetivo de este trabajo fue sintetizar la información existente hasta la fecha sobre las alteraciones neurocognitivas en pacientes con DD (TDM-DA). La búsqueda de artículos se realizó en las bases de datos ScienceDirect y PubMed con las palabras clave: diagnóstico dual, depresión, alcoholismo, funcionamiento cognitivo, desempeño neuropsicológico, déficit cognitivo y alteraciones cognitivas. Los hallazgos de los estudios referidos en este artículo sugieren que los pacientes con DD muestran alteraciones en dominios cognitivos específicos y que sus déficits no parecen mostrar un efecto aditivo de 2 trastornos independientes (AU)


The comorbidity between major depressive disorder (MDD) and alcohol dependence (AD) is known as dual diagnosis (DD). It has been suggested that patients with this comorbidity display a more severe autonomic and mood symptoms compared to patients with a single diagnosis. However, the additive effect of cognitive deficits in this population has hardly been studied. The objective of this study was to present a summary of the current information on neurocognitive alterations in patients with DD (MDD-AD). The search was conducted using ScienceDirect and PubMed with the keywords: dual diagnosis; depression; alcoholism; cognitive functioning; neuropsychological performance; cognitive impairment; cognitive impairment and neuropsychology. The findings of the studies reported in this paper suggest that patients with DD show impairment in specific cognitive domains; and that their deficits do not seem to show an additive effect of two separate disorders (AU)


Subject(s)
Humans , Depressive Disorder, Major/epidemiology , Alcoholism/epidemiology , Alcohol-Induced Disorders/epidemiology , Diagnosis, Dual (Psychiatry)/statistics & numerical data , Cognition Disorders/epidemiology
11.
Brain Cogn ; 84(1): 164-9, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24384089

ABSTRACT

Complex movement (CM) refers to the representation of a goal-oriented action and is classified as either transitive (use of tools) or intransitive (communication gestures). Both types of CM have three specific components: temporal, spatial, and content, which are subdivided into specific error types (SET). Since there is debate regarding the contribution of each brain hemisphere for the types of CM, our objective was to describe the brain lateralization of components and SET of transitive and intransitive CM. We studied 14 patients with a left hemisphere stroke (LH), 12 patients with a right hemisphere stroke (RH), and 16 control subjects. The Florida Apraxia Screening Test-Revised (FAST-R, Rothi et al., 1988) was used for the assessment of CM. Both clinical groups showed a worse performance than the control group on the total FAST-R and transitive movement scores (p<0.001). Failures in Spatial and Temporal components were found in both clinical groups, but only LH patients showed significantly more Content errors (p<0.01) than the control group. Also, only the LH group showed a higher number of errors for intransitive movements score (p=0.017), due to lower scores in the content component, compared to the control group (p=0.04). Transitive and intransitive CMs differ in their neurocognitive representation; transitive CM shows a bilateral distribution of its components when compared to intransitive CM, which shows a preferential left hemisphere representation. This could result from higher neurocognitive demands for movements that require use of tools, compared with more automatic communication gestures.


Subject(s)
Functional Laterality , Movement , Adult , Brain/pathology , Brain Ischemia/pathology , Brain Ischemia/psychology , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Stroke/pathology , Stroke/psychology
SELECTION OF CITATIONS
SEARCH DETAIL
...